Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

Lauren Brash, Gareth D. Barnes, Melanie J. Brewis, A. Colin Church, Simon J. Gibbs, Luke S.G.E. Howard, Geeshath Jayasekera, Martin K. Johnson, Neil McGlinchey, Joelle Onorato, Joanne Simpson, Colin Stirrat, Stephen Thomson, Geoffrey Watson, Martin R. Wilkins, Carrie Xu, David J. Welsh, David E. Newby, Andrew J. Peacock*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)
101 Downloads (Pure)


Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.

Original languageEnglish
Pages (from-to)176-186
Number of pages11
JournalJACC: Basic to Translational Science
Issue number2
Early online date28 Mar 2018
Publication statusPublished - Apr 2018


  • apelin pulmonary hypertension
  • apelin
  • APJ
  • human
  • pulmonary arterial hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this